Biden Cancer Summit – Center Director Jay Storm to Speak
On Friday, September 21st, Dr. Phillip “Jay” Storm CO-Director of the Center for Data Driven Discovery in Biomedicine joined the Biden Cancer Community Summit in Washington D.C. to present the commitment to “Double the Progress” through the Kids First Data Resource Center’s and the Children’s Brain Tumor Network to improving childhood disease research.
“The Biden Cancer Initiative is a great opportunity to highlight the open access cloud-based platforms that the Center for Data Driven Discovery in Biomedicine at CHOP has built in partnership with the NIH to breakdown siloes, facilitate collaboration and accelerate discovery.” Dr. Phillip “Jay” Storm, Chief of the Division of Neurosurgery at the Children’s Hospital of Philadelphia.
Vice President Joe Biden and Dr. Jill Biden are hosting the national Biden Cancer Summit to drive the urgency of now by promoting new solutions, bringing together problem solvers, and telling stories that epitomize what it means to be cancer FIERCE. The Summit in D.C. is the flagship event of more than 350 Biden Cancer Community Summits convening throughout September 21st, all focused on improving the cancer journey for patients, their families, and caregivers.
Dr. Storm will present the vision and mission of the Kids First Data Resource Center (DRC) the Kids First DRC Portal and highlight one of the pediatric cancer datasets available in the Kids First Data Resource Portal, the Pediatric Brain Tumor Atlas from the Children’s Brain Tumor Network. The Pediatric Brain Tumor Atlas data set includes more than 1,000 subjects across 30 pediatric brain tumor types with genomic, proteomic and imaging data.
Childhood Brain Tumor Network (CBTN) is a multi-institutional cooperative research program dedicated to the study of childhood brain tumors. The ultimate goal of the CBTN is to improve outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. With its operational center at CHOP, the mission of the CBTN is to collect high-quality brain tumor biospecimens with associated clinical data, facilitate genomic analysis of biospecimens, develop cell lines and transplantable tumor models from submitted biopsy specimens, and share results from these efforts with CBTN member institutions and the world-wide scientific community.
To achieve this mission, CBTN has established a multi-institutional, collaborative tissue repository and data registry designed to meet the need for high-quality brain tumor biopsy specimens along with relevant, comprehensive clinical data. The long-term goal of the CBTN is to actively stimulate tissue-based research and increase worldwide access to the molecular analysis of large numbers of brain tumor specimens by which new childhood brain tumor therapeutic targets can be developed and biologically-based prognostic factors essential to inform therapeutic decisions can be identified. The CBTN has over 2600 subject and 40,000 biospecimens.
#BidenCancerSummit #KidsFirstDRC #cbtn #PBTA #Collaboration4Cures